Our Model
Consortium Integrated by design. Aligned around your program.
Early-stage discovery moves at the speed of its feedback loops
A drug discovery program advances when design, synthesis, and biology share a single decision loop. Every handoff between separate teams costs time, dilutes context, and hides the trade-offs that actually move a series forward.
- Oxeltis has been a trusted partner in medicinal chemistry and complex organic synthesis since 2010.
To close the full loop of early-stage discovery, we built an integrated preclinical consortium: four independent specialists operating as one coordinated team, aligned around a single program, yours.
How it works
We operate as a single scientific consortium, not a subcontracting chain. Each partner keeps full ownership of its domain but works from a shared view of the program. Data, results, and decisions, including the dead ends, flow directly between teams rather than being repackaged into hand-off reports at each stage. Nothing waits on a formatted deliverable, and no context is lost in translation between vendors.
You work with one cohesive team through a single point of contact, fully aligned on your objectives. Engagement is scalable and transparent, tailored to your stage, your budget, and your priorities, resourced to the scope your program actually needs.
Four specialists, one decision loop
Each partner owns a distinct, best-in-class capability and contributes it to a shared, client-centric workflow.
Together we run the full DMTA cycle, Design, Make, Test, Analyze, under one coordinated umbrella, with genotoxicity risk flagged from the start.
The economics of specialization
An integrated solution is often assumed to cost more.
Each partner has spent years optimizing a single discipline. Molecular Forecaster runs lean on computational design, Oxeltis on medicinal chemistry and synthesis, Partex.AI Labs on biological validation, GenEvolutioN on early safety. None of them carries the cost of capabilities they don't provide. Every euro in their structure serves the expertise you are actually engaging in.
When these focused operations combine, the integrated price reflects delivered value, not the fixed overhead of a single large organization spread across every function. You are not paying for idle capacity, cross-subsidized departments, or infrastructure you never touch. You pay for the work, and for the coordination that keeps it moving as one.
The result is an engagement that is both scientifically complete and economically honest: full-cycle capability at the true cost of the expertise behind it, scaled to your program rather than to an institution's balance sheet.
What this means for your program
- No handoff friction.
Specialist expertise across the full cycle, without the loss of context that separate vendors impose.
- Faster iterations.
Tight feedback loops between modeling, synthesis, and biology.
- Smarter decisions.
Data-driven insight at every turn of the cycle, with safety signals surfaced early.
- Scalable engagement.
Transparent scope, aligned to your stage and budget.
Speed and Precision for Modern Drug Discovery
In a landscape where innovation demands both speed and precision, our consortium delivers both. We’re here to challenge the status quo and help you turn ideas into breakthroughs.
Ready to move faster?
Whether you are exploring new chemical entities, optimizing leads, or validating targets, our consortium is built to move as fast as your ambitions and as precisely as your science demands.
Tell us about your project. Let's build the path forward together.